These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31738425)

  • 1. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
    Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
    Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii31-viii35. PubMed ID: 32223937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.
    Corral Sánchez MD; Galán Gómez V; Sastre Urgelles A; Plaza López de Sabando D; Rubio Aparicio P; Martínez Martínez L; Alonso Gamarra E; Pozo Kreilinger JJ; Regojo Zapata RM; López Gutiérrez JC; Antolín Alvarado E; Gómez Martín F; Sánchez Torres AM; Marín Manzano E; González Del Valle L; Pérez-Martínez A
    Pediatr Hematol Oncol; 2021 Aug; 38(5):504-509. PubMed ID: 33622165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.
    Nagasubramanian R; Wei J; Gordon P; Rastatter JC; Cox MC; Pappo A
    Pediatr Blood Cancer; 2016 Aug; 63(8):1468-70. PubMed ID: 27093299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
    Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
    Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion.
    O'Reilly EM; Hechtman JF
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii36-viii40. PubMed ID: 31605106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series.
    Corral Sánchez MD; Jiménez Carrascoso R; Rubio Aparicio P; Plaza López de Sabando D; Sastre Urgelles A; Pozo-Kreilinger JJ; López Gutiérrez JC; Gómez Cervantes M; Ortiz Cruz EJ; Pérez-Martínez A
    Clin Transl Oncol; 2023 Nov; 25(11):3307-3311. PubMed ID: 37097530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib.
    Sahni S; Rastogi S; Yadav R; Barwad A
    Ecancermedicalscience; 2023; 17():1575. PubMed ID: 37533946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An infant with ETV6-NTRK3 fusion-positive congenital infantile fibrosarcoma and delayed response to conventional chemotherapy avoiding the need for TRK inhibition.
    Vedi A; Holland K; Cross J; Muthusamy B; Behjati S; Hook CE; Murray MJ
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28628. PubMed ID: 32748441
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study).
    Orbach D; Carton M; Khadir SK; Feuilly M; Kurtinecz M; Phil D; Vokuhl C; Koscielniak E; Pierron G; Lemelle L; Sparber-Sauer M
    ESMO Open; 2024 May; 9(5):103006. PubMed ID: 38657345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors.
    Motta M; Barresi S; Pizzi S; Bifano D; Lopez Marti J; Garrido-Pontnou M; Flex E; Bruselles A; Giovannoni I; Rotundo G; Fragale A; Tirelli V; Vallese S; Ciolfi A; Bisogno G; Alaggio R; Tartaglia M
    J Pathol; 2024 Jun; 263(2):166-177. PubMed ID: 38629245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
    Church AJ; Calicchio ML; Nardi V; Skalova A; Pinto A; Dillon DA; Gomez-Fernandez CR; Manoj N; Haimes JD; Stahl JA; Dela Cruz FS; Tannenbaum-Dvir S; Glade-Bender JL; Kung AL; DuBois SG; Kozakewich HP; Janeway KA; Perez-Atayde AR; Harris MH
    Mod Pathol; 2018 Mar; 31(3):463-473. PubMed ID: 29099503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infantile fibrosarcoma-like tumor driven by novel
    Gupta A; Belsky JA; Schieffer KM; Leraas K; Varga E; McGrath SD; Koo SC; Magrini V; Wilson RK; White P; Mardis ER; Jatana KR; Cottrell CE; Setty BA
    Cold Spring Harb Mol Case Stud; 2020 Oct; 6(5):. PubMed ID: 33028644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second Report of
    Hughes CE; Correa H; Benedetti DJ; Smith B; Sumegi J; Bridge J
    Pediatr Dev Pathol; 2021; 24(6):554-558. PubMed ID: 34120511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
    Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
    Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.